Mode
Text Size
Log in / Sign up
N/A N=296 Randomized Treatment

Behavioral Approaches to Reducing Diabetes Distress and Improving Glycemic Control

Type 1 Diabetes · Diabetes Distress

Enrolled (actual)
296
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Diabetes Distress at 12 Months — 2.34; 2.03; 2.06 score on a scale — p=.007

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
StreamLine (Behavioral); TunedIn (Behavioral); FixIt (Behavioral)
Age
Adult, Older Adult · 19+ yrs
Sex
All
Sponsor
University of California, San Francisco
Primary completion
Feb 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Diabetes Distress at 12 Months
2.34; 2.03; 2.06 .007 sig
PRIMARY
Hemoglobin A1c (HbA1c) at 12 Months
7.52; 7.60; 7.94 .006 sig
SECONDARY
Hypoglycemic Episodes at 12 Months
1.17; 1.32; 1.23 0.82
SECONDARY
Depression Symptoms at 12 Months
6.35; 5.94; 7.09 .01 sig
SECONDARY
Missed Insulin Boluses at 12 Months
0.15; 0.17; 0.19 .40
SECONDARY
Nonreactivity to Inner Experience at 12 Months
23.68; 24.34; 24.22
SECONDARY
Non-judging of Experience at 12 Months
31.29; 32.13; 30.48 .12
SECONDARY
Personal Control Over Illness at 12 Months
24.77; 24.68; 24.99 .39
SECONDARY
Self-compassion - Diabetes (SCS-D) at 12 Months
3.42; 3.60; 3.44 <.01 sig

Summary

This study is comparing three programs to reduce Diabetes Distress (the worries and concerns that people with diabetes may experience as they struggle to keep blood glucose levels in range) in adults with type 1 diabetes. About a third of participants will take part in the TunedIn program, about a third will take part in the FixIt program, and about a third in the StreamLine program.

Eligibility Criteria

Inclusion Criteria

  • Adult patients with type 1 diabetes (confirmed by clinical history and/or anti-glutamic acid decarboxylase] antibody testing) on intensive insulin treatment;
  • Diagnosis of type 1 diabetes for at least 12 months that occurred at or below age 40;
  • Have a recent HbA1c of 7.5% or higher;
  • Not have started to use any new (to the participant) diabetes device (such as an insulin pump or continuous glucose monitor) in the past 6 months;
  • Internet access through a computer or smart phone;
  • Ability to speak/read English.

Exclusion Criteria

  • No documented psychosis, blindness, dementia, active dialysis, substance abuse, amputations, or severe functional deficits, or recent major surgery or hospitalization in the past year.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04016558). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search